Pardis Ahmadi

Pardis Ahmadi

Auto-generated profile, based on publicly available information

Pardis Ahmadi

Columbia University Irving Medical Center 1 Institute for Cancer Genetics, Department of Genetics and Development New York, New York

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 November 2023 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
PAPardis Ahmadi
Pardis Ahmadi
JVJaleh Varshosaz
Jaleh Varshosaz
FHFarshid Hassanzadeh
Farshid Hassanzadeh
Mina MirianMina Mirian
Mina Mirian
Hajar SirousHajar Sirous
Hajar Sirous

14 August 2026
Verified
Other
Open access
PDF file
JPJustin Powers
Justin Powers
LWLai Wei
Lai Wei
JCJustin Chak Ting Cheung
Justin Chak Ting Cheung
PAPardis Ahmadi
Pardis Ahmadi
HKHiroki Kobayashi
Hiroki Kobayashi
CCChristine Chio
Christine Chio
Quality assessment and validation of the genome-wide CRISPR screen.

14 August 2026
Verified
Other
Open access
PDF file
JPJustin Powers
Justin Powers
LWLai Wei
Lai Wei
JCJustin Chak Ting Cheung
Justin Chak Ting Cheung
PAPardis Ahmadi
Pardis Ahmadi
HKHiroki Kobayashi
Hiroki Kobayashi
CCChristine Chio
Christine Chio
Loss of eIF4G2 does not alter global protein synthesis.

14 August 2026
Verified
Other
Open access
JPJustin Powers
Justin Powers
LWLai Wei
Lai Wei
JCJustin Chak Ting Cheung
Justin Chak Ting Cheung
PAPardis Ahmadi
Pardis Ahmadi
HKHiroki Kobayashi
Hiroki Kobayashi
CCChristine Chio
Christine Chio
List of differentially expressed transcripts in sgEif4g2 PDAC cells compared to sgRosa control PDAC cells.

14 August 2026
Verified
Other
Open access
JPJustin Powers
Justin Powers
LWLai Wei
Lai Wei
JCJustin Chak Ting Cheung
Justin Chak Ting Cheung
PAPardis Ahmadi
Pardis Ahmadi
HKHiroki Kobayashi
Hiroki Kobayashi
CCChristine Chio
Christine Chio
Translationally downregulated transcripts with matching protein decreases in sgEif4g2 vs sgRosa PDAC cells.

14 August 2026
Verified
Other
Open access
JPJustin Powers
Justin Powers
LWLai Wei
Lai Wei
JCJustin Chak Ting Cheung
Justin Chak Ting Cheung
PAPardis Ahmadi
Pardis Ahmadi
HKHiroki Kobayashi
Hiroki Kobayashi
CCChristine Chio
Christine Chio
The lethality of pancreatic ductal adenocarcinoma (PDAC) is driven, in part, by cellular plasticity that facilitates dedifferentiation and dissemination. Although transcriptional programs underlying these processes are well characterized, the contribution of translational control to PDAC cell-state regulation in vivo needs to be further understood to develop strategies to restrain malignant plasticity. Using a genome-wide CRISPR/Cas9 screen in immunocompetent hosts, we identified the noncanonical initiation factor eIF4G2 (DAP5/NAT1) as a translational checkpoint that restrains PDAC progression. Loss of eIF4G2 accelerated tumor growth, promoted poorly differentiated, basal-like histology, and triggered widespread metastasis. Ribosome profiling revealed that eIF4G2 supports the translation of a discrete cohort of mRNAs with long, guanine-cytosine (GC)-rich, structured 5′ untranslated regions, including tumor suppressors such as Pten and transcriptional regulators such as Crebbp. Accordingly, loss of eIF4G2 was accompanied by secondary transcriptional enrichment of migration and wound-healing programs and induction of basal-like markers. In human PDAC, eIF4G2 expression was reduced in poorly differentiated lesions, and functional eIF4G2 perturbation in patient-derived PDAC cells increased clonogenic growth, whereas enforced eIF4G2 expression suppressed colony formation. Computational inference from human PDAC datasets revealed that reduced eIF4G2 activity correlated with increased metastasis, enhanced basal-like features, and poorer patient survival. Together, these findings establish noncanonical translation initiation as a determinant of PDAC cell-state control and identify eIF4G2 as a barrier to malignant plasticity and metastatic dissemination. Significance:The translational checkpoint regulator eIF4G2 preserves epithelial identity and suppresses metastasis in pancreatic cancer, revealing selective translation as a determinant of subtype, prognosis, and therapeutic stratification.